TLSA

Today, 7:05 AMTiziana Life Sciences: intranasal foralumab meets dual primary endpoints in Phase 2a INFORM-MS trial in non-active SPMS

Peers: IMUX COYA CLNN INMB ACIU ALEC AVXL ANNX ANVS TNXP

Scroll to Statements

Index	-
Market Cap	108.50M
Enterprise Value	106.25M
Income	-25.19M
Sales	0.00M
Book/sh	-0.02
Cash/sh	0.02
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	10
IPO	Nov 20, 2018

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	34.12
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	0.69
Current Ratio	0.69
Debt/Eq	-
LT Debt/Eq	-
Option/Short	Yes / Yes

EPS (ttm)	-0.20
EPS next Y	-0.18
EPS next Q	-
EPS this Y	-5.18%
EPS next Y	-5.87%
EPS next 5Y	-4.82%
EPS past 3/5Y	-0.89% -0.19%
Sales past 3/5Y	- -
EPS Y/Y TTM	-78.92%
Sales Y/Y TTM	-
EPS Q/Q	-101.04%
Sales Q/Q	-
Earnings	Sep 18
EPS/Sales Surpr.	1.50% -

Insider Own	49.84%
Insider Trans	1.57%
Inst Own	2.02%
Inst Trans	-14.81%
ROA	-178.26%
ROE	-780.60%
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-15.84%
SMA50	-15.37%
SMA200	-30.17%
Trades

Shs Outstand	128.03M
Shs Float	64.36M
Short Float	4.34%
Short Ratio	3.57
Short Interest	2.79M
52W High	1.96 -56.86%
52W Low	0.76 11.04%
Volatility	9.81% 7.61%
ATR (14)	0.08
RSI (14)	38.34
Beta	0.49
Rel Volume	10.07
Avg Volume	782.44K
Volume	393,872

Perf Week	-4.16%
Perf Month	-24.50%
Perf Quarter	-12.61%
Perf Half Y	-39.17%
Perf YTD	-43.25%
Perf Year	-55.96%
Perf 3Y	29.20%
Perf 5Y	-47.48%
Perf 10Y	-
Recom	1.00
Target Price	7.97
Prev Close	0.80
Price	0.85
Change %	5.70%

Consensus

Strong Buy

Avg. Price Target

$7.97

Implied Upside

+842.5%

Analysts3incl. previous ratings

Rating Distribution3 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Sep 03, 2026	Initiated	BBTIG Research	Buy	$7	+727.8%
Dec 22, 2020	Initiated	RB. Riley Securities	Buy	$8	+846.1%
Dec 17, 2018	Initiated	LLaidlaw	Buy

Today 07:00AM	Tiziana Announces Positive Topline Results from Phase 2a INFORM-MS Trial of Intranasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis (GlobeNewswire) +5.70%
Oct-21-26 07:00AM	Tiziana Management Team to Attend the 10th Joint ACTRIMS-ECTRIMS Meeting in Toronto (GlobeNewswire)
Oct-16-26 08:38AM	Tiziana completes dosing in Phase 2 Alzheimers trial of intranasal foralumab (Proactive)
07:00AM	Tiziana Doses Last Patient in Phase 2 Trial of Intranasal Foralumab for Mild Alzheimer's Disease (GlobeNewswire)
Sep-30-26 08:54AM	Tiziana Life Sciences seeks FDA orphan drug status for nasal MSA therapy (Proactive) +16.39%
07:14AM	Loading…
07:14AM	MARKETS LIVE: Wall Street closes mixed as cooling inflation lifts Nasdaq (Proactive)
07:00AM	Tiziana Life Sciences Files for Orphan Drug Designation with the FDA for Intranasal Foralumab for the Treatment of Multiple System Atrophy (MSA) (GlobeNewswire)
Sep-28-26 09:14AM	Tiziana doses first three patients in ALS trial of nasal antibody foralumab (Proactive)
07:00AM	Tiziana Life Sciences Announces First Participants Dosed in ALS BANYAN Clinical Trial of Intranasal Foralumab (GlobeNewswire)
Sep-21-26 09:28AM	Tiziana Life Sciences completes patient visits in Phase 2a MS drug trial (Proactive)
07:00AM	Tiziana Announces Last Patient Completes Last Visit in Phase 2a INFORM-MS Trial of Intranasal Foralumab (GlobeNewswire)
Sep-17-26 09:39AM	Tiziana Life Sciences partners with Saudi institutions on MS combination therapy trial (Proactive) +25.96%
07:00AM	Tiziana Life Sciences Announces Signing of MOU with King Abdullah International Medical Research Center (GlobeNewswire)
Sep-03-26 03:09PM	Tiziana Life Sciences gets Buy rating from BTIG on Treg-based approach to neurodegeneration (Proactive)
Aug-24-26 08:35AM	Tiziana Life Sciences to present Phase 2a BANYAN trial data at ALS Nexus 2026 (Proactive)
08:05AM	Loading…
08:05AM	Wall Street ends on a mixed note as Dow gains despite semiconductor slump (Proactive)
08:05AM	Dow edges higher while technology shares pull Nasdaq, S&P lower (Proactive)
07:00AM	Tiziana Life Sciences Announces Poster Presentation on Phase 2a BANYAN Clinical Trial of Intranasal Foralumab at ALS Nexus 2026 (GlobeNewswire)
Aug-06-26 07:00AM	Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer (GlobeNewswire)
Aug-04-26 07:00AM	Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer (GlobeNewswire)
Jul-31-26 08:55AM	Tiziana Life Sciences reports reductions in brain inflammation in third MSA patient (Proactive) +6.19%
07:00AM	Tiziana Reports Reduction in Brain Inflammation in Third Multiple System Atrophy Patient Treated with Intranasal Foralumab (GlobeNewswire)
Jul-22-26 07:00AM	Tiziana Life Sciences Announces Purchase of Shares by Executive Chairman (GlobeNewswire) -5.50%
Jun-25-26 09:05AM	Tiziana Life Sciences doses last patient in Phase 2a multiple sclerosis trial (Proactive)
07:00AM	Tiziana Announces Last Patient Successfully Dosed in its Phase 2 INFORM-MS Trial (GlobeNewswire)
Jun-15-26 07:00AM	Tiziana Life Sciences Announces Purchase of Shares by Executive Chairman (GlobeNewswire)
May-28-26 07:00AM	Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference in New York (GlobeNewswire)
May-22-26 04:48PM	Tiziana Life Sciences advances foralumab program with full Phase 2 enrollment and encouraging expanded access data ICYMI (Proactive)
May-21-26 11:44AM	Tiziana Life Sciences completes enrollment in Phase 2a multiple sclerosis trial (Proactive) -9.32%
11:00AM	Tiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis Trial (GlobeNewswire)
03:12PM	Loading…
May-19-26 03:12PM	Tiziana Life Sciences price target boosted on foralumab update (Proactive)
09:42AM	Tiziana Life Sciences reports encouraging one-year data for intranasal foralumab in progressive MS (Proactive)
07:00AM	Tiziana Announces New Positive Clinical Data for Intranasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis (GlobeNewswire)
May-14-26 09:06AM	Tiziana Life Sciences reports brain inflammation reductions in Multiple System Atrophy trial (Proactive)
07:00AM	Tiziana Reports Reduced Brain Inflammation in Multiple System Atrophy Patients Treated with Intranasal Foralumab (GlobeNewswire)
Apr-22-26 06:03PM	Inventiva Builds Up Leadership Team Ahead of Potential Commercialization (Exec Edge)
Apr-16-26 08:58AM	Tiziana says intranasal drug shows potential to ease Long COVID brain fog (Proactive)
07:00AM	Tiziana Life Sciences Announces Publication of Positive Data Demonstrating Intranasal Anti-CD3 Antibody Attenuates Long COVID Neuroinflammation and Improves Cognitive Function (GlobeNewswire)
Apr-14-26 07:00AM	Tiziana Life Sciences Announces Late Breaking Poster Accepted for Presentation at the 7th World Parkinson Congress (GlobeNewswire) +12.17%
04:56AM	Tiziana Life Sciences to present Phase 2a MSA study at World Parkinson Congress (Proactive)
Apr-01-26 10:19AM	Tiziana Life Sciences reports positive preclinical findings for intranasal anti-CD3 therapy in brain aging (Proactive) +6.84%
07:00AM	Tiziana Announces Data Showing Nasal Anti-CD3 Improves Cognition Associated with Aging (GlobeNewswire)
Feb-25-26 10:40AM	Tiziana reports biomarker gains for nasal MS therapy in progressive disease (Proactive)
07:00AM	Tiziana Life Sciences Announces New Biomarker Data Showing Nasal Foralumab Downregulates CSF Inflammation, Upregulates Neuroprotective Pathways, and Correlates with Reduced Microglial Activation on PET Scans in na-SPMS Patients with PIRA (GlobeNewswire)
Jan-20-26 11:15AM	Tiziana Life Sciences Announces the Peer-Reviewed Publication of Clinical Study Results for Intranasal Foralumab (GlobeNewswire) -5.95%
Jan-16-26 02:45PM	Tiziana Life Sciences Announces Closing of Oversubscribed $8.8 Million Registered Direct Offering of Ordinary Shares (GlobeNewswire) +15.86%
07:00AM	Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $17.6 Million (GlobeNewswire)
Jan-09-26 07:00AM	Tiziana Life Sciences to Present at the 9th Annual Neuroscience Innovation Forum During J.P. Morgan Healthcare Conference Week in San Francisco (GlobeNewswire)
Dec-30-25 08:15AM	Tiziana Life Sciences files annual safety report for intranasal foralumab (TipRanks)
Dec-29-25 08:00AM	Tiziana Files Annual Safety Report for Intranasal Foralumab with FDA (GlobeNewswire)
Dec-19-25 11:00AM	Tiziana Life Sciences Announces Acquisition of Shares by Executive Chairman (GlobeNewswire) +5.56%
Dec-17-25 10:00AM	Tiziana Life Sciences to Ring the Closing Bell at Nasdaq (GlobeNewswire) -5.81%
08:45AM	Tiziana Life Sciences Doses First Patient in Phase 2 Alzheimer's Clinical Trial (GlobeNewswire)
Dec-15-25 03:07PM	Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer (GlobeNewswire) -10.67%
07:30AM	Tiziana Life Sciences Announces Withdrawal of Proposed Public Offering (GlobeNewswire)
Dec-12-25 02:10PM	Tiziana Life Sciences to Dose First Patient in Phase 2 Alzheimer's Trial (GlobeNewswire)
Dec-02-25 07:00AM	Tiziana Life Sciences Plans to Spinout IL-6 Asset into Separate Listed Company (GlobeNewswire)
Nov-25-25 08:30AM	Tiziana Life Sciences Nasal Foralumab Phase 2 Clinical Trial Accepted into Healey ALS MyMatch Program (GlobeNewswire) +5.20%
Nov-13-25 08:30AM	Tiziana Life Sciences to Present at Jefferies Global Healthcare Conference (GlobeNewswire) -7.30%
Oct-29-25 07:00AM	Tiziana Life Sciences to Present at BIO-Europe in Vienna, Highlighting Innovative Immunomodulation Therapy (GlobeNewswire)
Sep-30-25 08:30AM	Tiziana Life Sciences Invited to Attend Life Sciences Innovation Forum 2025 in Riyadh, Saudi Arabia (GlobeNewswire)
Sep-25-25 08:30AM	Tiziana to Advance TZLS-501 - Its Fully Human IL-6R Monoclonal Antibody (GlobeNewswire) +5.08%
Sep-24-25 08:30AM	Tiziana Life Sciences Announces Poster Presentation on Intranasal Foralumab Clinical Trial at the 41st ECTRIMS Congress (GlobeNewswire) +11.93%
Sep-23-25 07:24PM	Tiziana Life Sciences Ltd (TLSA) Secures U.S. DoD Grant to Advance Intranasal Foralumab for Spinal Cord Injury (Insider Monkey)
Sep-15-25 08:00AM	Department of Defense Awards Grant to Advance Tiziana Life Sciences Intranasal Anti-CD3 Therapy for Spinal Cord Injury (GlobeNewswire)
Sep-09-25 10:04AM	Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer (GlobeNewswire) +14.20%
Sep-05-25 08:30AM	Tiziana Life Sciences Announces Purchase of Shares by Chairman (GlobeNewswire) +5.06%
Aug-14-25 08:30AM	Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab for Multiple System Atrophy (GlobeNewswire) -6.10%
Aug-11-25 09:00AM	FDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System Atrophy (GlobeNewswire) +11.82%
Jul-21-25 07:00AM	Tiziana Life Sciences Announces Immunologic Analysis of Nasal Foralumab in Moderate Alzheimer's Patient (GlobeNewswire)
Jun-13-25 10:30AM	Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center (GlobeNewswire) +9.15%
08:30AM	Tiziana Life Sciences to Present at the Bio International Convention (GlobeNewswire)
May-23-25 07:00AM	Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer's Disease (GlobeNewswire) +15.33%
May-15-25 08:00AM	Journal of Clinical Nuclear Medicine Publishes Results of Tiziana's Nasal Foralumab in Study Treating Moderate Alzheimer's Disease (GlobeNewswire)
May-12-25 07:00AM	Tiziana Life Sciences Announces Purchase of Shares by Chairman (GlobeNewswire)
May-09-25 07:00AM	Tiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer's Patient Treated with Intranasal Foralumab (GlobeNewswire)
May-06-25 07:00AM	Tiziana Life Sciences Announces Comprehensive Positive Results from Study of Nasal Foralumab in Patients with Multiple Sclerosis (GlobeNewswire) +22.95%
Apr-30-25 05:39AM	Why Tiziana Life Sciences Ltd (TLSA) is Surging in 2025 (Insider Monkey) +9.68%
Apr-24-25 11:14AM	Dosing begins in Tiziana Life Sciences trial of foralumab for na-SPMS (Clinical Trials Arena) +9.92%
Apr-23-25 07:00AM	Tiziana Life Sciences Announces University of Massachusetts Commences Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial (GlobeNewswire) +12.93%
Apr-02-25 08:00AM	Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical Trial (GlobeNewswire)
Mar-26-25 07:58AM	Tiziana Life Sciences begins dosing in trial of therapy for multiple sclerosis (Clinical Trials Arena)
Mar-25-25 08:00AM	Tiziana Life Sciences Announces Yale University Commences Intranasal Foralumab Dosing in Phase 2 Multiple Sclerosis Trial (GlobeNewswire) +13.89%
Mar-17-25 08:00AM	Tiziana Life Sciences to Present at the 37th Annual Roth Conference (GlobeNewswire)
Mar-14-25 08:30AM	Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule (GlobeNewswire) +6.08%
Mar-04-25 08:00AM	Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial (GlobeNewswire)
Mar-02-25 09:25AM	Why Tiziana Life Sciences Ltd (TLSA) is Skyrocketing So Far in 2025 (Insider Monkey)
Feb-27-25 08:00AM	Tiziana Life Sciences Announces Groundbreaking Study Published in Nature Neuroscience Demonstrating Positive Results for Nasal Anti-CD3 Therapy in Traumatic Brain Injury (GlobeNewswire) +15.31%
Feb-25-25 08:00AM	Tiziana Life Sciences Announces Long Covid Study to Complete in Second Quarter (GlobeNewswire) +6.07%
Feb-21-25 08:00AM	Tiziana Life Sciences Announces Agreement for Product Development Services with Renaissance Lakewood, LLC (GlobeNewswire) -8.90%
Feb-18-25 08:00AM	Tiziana Life Sciences Announces Dosing of Additional Patients in Multiple Sclerosis Expanded Access Program (GlobeNewswire) +11.07%
Feb-11-25 09:15AM	Tiziana Life Sciences Announces TV Interview with First Patient Dosed with Moderate Alzheimer's Disease (GlobeNewswire)
Jan-23-25 03:00PM	Tiziana Life Sciences Announces Positive Results in Treating Spinal Cord Injury With Nasal Anti-CD3 (GlobeNewswire) +11.06%
08:54AM	Tiziana Life Sciences not to engage in capital raising activities for the immediate future (GlobeNewswire)
Jan-22-25 04:05PM	Tiziana Life Sciences Announces Discovery of New Immune Biomarkers in Multiple Sclerosis Patients Treated with Nasal Foralumab (GlobeNewswire) +8.51%
Jan-10-25 08:00AM	Tiziana Announces Reduction of Side Effects Commonly Seen with Discontinuation of GLP-1 Agonists with Nasal Anti-CD3 (GlobeNewswire) +14.13%
Jan-08-25 07:00AM	Tiziana Life Sciences Announces Review Article Published in Nature Highlighting Foralumab's Potential in the Treatment of Neurological Disease (GlobeNewswire)
Dec-17-24 07:00AM	Tiziana Life Sciences Announces First Patient with Moderate Alzheimer's Disease Dosed with Intranasal Foralumab (GlobeNewswire) +6.50%
Dec-05-24 07:07AM	Tiziana Life Sciences expands Phase 2 trial for non-active SPMS (TipRanks)
Dec-04-24 07:00AM	Tiziana Life Sciences Expands Phase 2 Clinical Trial for Non-Active Secondary Progressive Multiple Sclerosis to Additional Prestigious U.S. Medical Centers (GlobeNewswire) +12.09%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Elrifi Ivor	Chief Executive Officer	Aug 05 '26	Buy	1.00	237,616	237,616	4,793,684	Aug 06 09:30 AM
Elrifi Ivor	Chief Executive Officer	Aug 04 '26	Buy	0.97	83,807	81,293	4,556,068	Aug 06 09:30 AM
Elrifi Ivor	Chief Executive Officer	Aug 03 '26	Buy	1.00	667,000	667,000	4,472,261	Aug 05 04:30 PM

Tiziana Life Sciences Ltd. is a clinical-stage biotechnology company, which engages in developing therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, Amyotrophic Lateral Sclerosis, and Alzheimer's. The company was founded by Gabriele Marco Antonio Cerrone on February 11, 1998 and is headquartered in London, the United Kingdom.

Founder & Executive ChairmanMr. Gabriele Marco Antonio Cerrone M.B.A.

COO & CFOMs. Keeren Shah

CEO & Executive DirectorDr. Ivor R. Elrifi Ph.D.

Chief Regulatory OfficerMr. William Edward Tente M.S.

Chief Medical OfficerDr. Richard K. Kim M.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Tiziana Life Sciences Ltd

Upgrade your Finviz experience